Trastuzumab Deruxtecan (DS8201) Rescue Advanced Her2 Low Expression Breast Cancer: A Case Report and Review of Literature
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).46Keywords:
Trastuzumab deruxtecan, HER2 low- expressing breast cancer, Breast cancer brain metastasis, Breast cancer liver metastasisAbstract
HER2 low-expression subtype breast cancer has not yet been included in the guidelines, so there are fewer drugs available for this type of breast cancer. The new drug Trastuzumab deruxtecan (DS8201) can be used for the treatment of HER2 low-expression subtype breast cancer, which is suitable for patients with non-surgically resectable or metastatic HER2 low-expression subtype breast cancer. We hereby report a case of using Trastuzumab deruxtecan to rescue an advanced HER2 low expression subtype breast cancer patient in our clinical admission process, in order to provide new treatment ideas for HER2 low expression patients.
References
Sung Hyuna, Ferlay Jacques, Siegel Rebecca L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA:A Cancer Journal for Clinicians, 2021,71(3):209-249.
Noone Anne-Michelle, Cronin Kathleen A, Altekruse Sean F, et al. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. [J]. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, 26(4):632-641.
Moy Beverly, Rumble R Bryan, Carey Lisa A, et al. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2022, 40(26): JCO2201533-JCO2201533.
Kuksis Markus, Gao Yizhuo, Tran William, et al. The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.[J].Neuro-oncology,2020,23(6):894-904.
Hoe AL, Royle GT, Taylor I. Breast cancer and liver metastases--incidence, diagnosis and outcome. [J]. Proceedings of the Royal Society of Medicine, 1992, 85(8):508.
Xin Ling, Wu Qian, Zhan Chongming, et al. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021).[J]. Chinese medical journal, 2022, 135(6):697-706.
Zhang Guochun, Ren Chongyang, Li Cheukfai, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Medicine, 2022, 20(1):142-142.
ZHU Xiaojuan, ZHANG Hong, ZHANG Shuang, et al. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University. Health sciences, 2023, 55(2):243-253.
BAI Bing, ZHANG Aijia, GUO Xin, et a l. Analysis of clinicopathological features and prognostic factors in HER2 low expression breast cancer[J]. Journal of China Medical University, 2023, 52(0 6):494-498.
Di Cosimo Serena, La Rocca Eliana, Ljevar Silva, et al. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world[J]. Frontiers in Molecular Biosciences, 2022, 9:996434-996434.
Denkert Carsten, Seither Fenja, Schneeweiss Andreas, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.[J]. The Lancet. Oncology, 2021, 22(8):1151-1161.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Wenhao Mao, Chang Yao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
